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ABSTRACT 
Purpose: To assess the baseline variation in global renal and tumour blood flow, blood volume and extraction 
fraction, and changes in these parameters related to the acute physiological effects of a single dose of a non selec-
tive inhibitor of nitric oxide synthase, L-NNA. Materials & Methods: Ethical approval and informed consent were 
obtained for this Phase I clinical study. Patients with advanced solid tumours refractory to conventional therapy 
were recruited and given L-NNA intravenously at two different dose levels. Volumetric perfusion CT scans were 
carried out at 1, 24, 48 & 72 hours post L-NNA. Blood pressures were taken at regular interval for 6 hours after 
LNNA. Results: L-NNA was well tolerated by the four patients who received it. Blood flow (BF) and blood vo-
lume (BV) in both tumour and kidney were reduced post L-NNA administration (renal BF—20%; renal BV— 
19.7%; tumour BF—16.9%; tumour BV—18.6%), though the effect was more sustained in tumour vasculature. 
A negative correlation was found between the change in systemic blood pressure and vascular supply to the tu-
mour within 1 hour following L-NNA (p < 0.0001). Differences in response to L-NNA by separate target lesions 
in the same patient were observed. Conclusion: The differential effect of L-NNA on tumour and renal blood flow, 
and the absence of any significant toxicity in this small cohort of patients permit further dose escalation of 
L-NNA in future early phase trials. The predictive value of blood pressure change in relation to the acute effect 
of L-NNA on tumour vasculature deserves further evaluation. 
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1. Introduction 
Nitric oxide (NO) is involved in the regulation of a wide 
range of physiological processes such as blood flow, 
neurotransmission, cell migration and immune responses. 
It is also implicated in the development and progression 
of cancer by mediating tumour angiogenesis and metas-
tasis [1,2]. Its synthesis from arginine is catalysed by  
isoforms of nitric oxide synthase (NOS). Blockade of the 
NOS pathway has long been identified as a potential 
pharmacological target in the treatment of cancer, and in 
preclinical studies, NOS blockade has a differential ef-
fect on systemic and tumour perfusion [3].  
As nitric oxide plays a role in the maintenance of renal 
perfusion and blood flow in the systemic vasculature,  
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blockade of the NOS pathway can result in renal toxici-
ties and the development of hypertension [4,5]. Thus, in 
order to establish the optimal dosage of an anti-NOS 
treatment in an early phase trial it is necessary to monitor 
changes in blood pressure and renal blood flow post ad-
ministration. Whilst blood pressure can be readily meas-
ured, assessment of renal perfusion requires a more inva-
sive approach. Using imaging techniques such as dy-
namic contrast enhanced computed tomography (CT; 
also known as Perfusion CT) global renal perfusion may 
be evaluated via kinetic modelling of renal enhancement 
changes following intravenous administration of CT con-
trast agent. These techniques may also provide unique in- 
formation of the differential effect of anti-vascular drugs 
on the tumour and systemic vasculature. 
We report the use of volumetric helical perfusion CT 
(vPCT) in evaluating the acute physiological effects of a 
non-selective inhibitor of nitric oxide synthase, NG-Ni- 
tro-L-arginine hydrochloride (L-NNA) on renal vascular-
ity, blood pressure, and tumour perfusion in cancer pa-
tients participating in a Phase 1 clinical trial. The primary 
objective of this trial was to evaluate the differential res-
ponses between tumour and renal vasculature following 
L-NNA administration in human subjects. This was 
achieved by assessing the baseline variation in global 
renal and tumour blood flow, blood volume and extrac-
tion fraction, and changes in these parameters related to 
the acute physiological effects of a single dose of L- 
NNA. 
2. Methods & Materials 
2.1. Ethical Approval, Sponsorship & 
Registration 
The conduct of this prospective Phase 1 trial was ap-
proved by the national research ethics committee. This 
trial was undertaken under the sponsorship and manage-
ment of Cancer Research UK’s Drug Development Of-
fice and registered with the European Union Drug Regu-
lating Authorities Clinical Trials of the European Medi-
cines Agency (EudraCT number: 2009-013621-42). Writ- 
ten informed consent was obtained from all patients. 
2.2. Patient Eligibility 
Inclusion criteria included: age > 18 years; life expec-
tancy of at least 12 weeks; WHO performance status of 0 
or 1; disease assessable by vPCT and at least 2 cm meas-
ured on the longest axis and adequate haematological, 
liver and renal function. 
Exclusion criteria included: histological diagnosis of 
squamous cell carcinoma; history of hypertension or cur- 
rent use of anti-hypertensive medication; history of is- 
chemic heart disease, peripheral vascular disease or di-
abetes; history of thromboembolic or cerebrovascular 
disease; current use of anti-coagulation, angiotensin con- 
verting enzyme inhibitors or nitrate.  
From July 2011 to January 2012, a total of 61 patients 
were considered for the study. Of these 13 gave informed 
consent and were screened, of which 6 were enrolled and 
4 of these patients were administered L-NNA.  
2.3. Administration of L-NNA and Blood 
Pressure Monitoring 
L-NNA was administered through a volumetric pump 
(PLUM A+ infusion system, Hospira, Illinois, USA) 
through a peripheral intravenous catheter as a 100 ml in- 
fusion over 10 minutes. Blood pressure was measured by 
an automated device (Datascope Passport XG, Phillips, 
Amsterdam, Netherlands) before the start of treatment 
and at the following time points following the infusion of 
L-NNA: 20 minutes, 40 minutes, 60 minutes, 1 hour, 1 
hour 45 minutes, 2 hours, 2 hours 30 minutes, 3 hours, 3 
hours 30 minutes, 4 hours and 6 hours. The mean arterial 
blood pressure was calculated as 2/3 diastolic blood pres- 
sure + 1/3 systolic blood pressure [6]. 
2.4. Measurement of Renal and Tumour 
Vascularity with vPCT 
All imaging was performed on a Dual Source CT scanner 
(Somatom Definition, Siemens Healthcare, Forchheim, 
Germany). A breath-held, low dose planning acquisition 
to locate both the tumor and the kidneys was performed 
initially with the acquisition parameters as shown in Ta-
ble 1. The 4D adaptive spiral acquisitions centred on the 
kidneys and tumour were planned from this study, and 
consisted of successive craniocaudal and caudocranial 
acquisitions, with a variable pitch of 1 at the central point 
of the table travel and <1 in the accelerating and decele-
rating portions, which guarantees a full rotation is avail-
able for reconstruction. The maximum dose limit permit-
ted by the ethics committee was 25 mSv per vPCT study, 
and an adaptive acquisition approach was applied to en-
sure that this was adhered to. 
To assess baseline reproducibility, two separate base-
line vPCTs were performed within 24 hours of each other, 
up to one week before L-NNA administration. Following 
the infusion of L-NNA, vPCTs were carried out with the 
following scheduled time-points: 1 hour, 24 hours, 48 
hours & 72 hours post drug administration. 
2.4.1. Renal Acquisition 
50 millilitres of iodinated contrast agent (ioversol 350 
mg/ml iodine; Optiray, Covidien, Mansfield, MA, USA) 
was administered intravenously at 5 ml/s using a dual 
headed pump injector (OptiVantage™ DH, Mallinckrodt, 
St Louis, Missouri, USA), followed by a 30 millilitres of  
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Table 1. Low dose preliminary scans. 
 Head Chest Abdomen Pelvis 
kV 120 80 80 80 
Effective mAs 370 70 70 70 
Rotation time (s) 1 0.5 0.5 0.5 
Detectors 20 × 0.6 mm 24 × 1.2 mm 24 × 1.2 mm 24 × 1.2 mm 
Pitch 0.55 1.2 1.2 1.2 
Slice collimation 5 mm 5 mm 5 mm 5 mm 
Dynamic scans 
 Head Chest Abdomen Pelvis 
kV 80 80 100 100 
mAs 200 120 110 110 
Rotation time (s) 0.33 0.33 0.33 0.33 
Pitch Up top max of 1 
Slice thickness 
(mm) 10, 5, 1.5 5, 3, 1.5 5, 3, 1.5 5, 3, 1.5 
Increment (mm) 4, 3, 1 3, 2, 1 3, 2, 1 3, 2, 1 
Coverage (mm) 48 114 62 62 
Delay (s) 4 4 4 10 
 
saline flush at the same rate. After a delay of 10 s from 
the start of the injection, the breath-held post contrast 
dynamic 4D adaptive spiral acquisition centred on both 
kidneys was obtained. To optimise breath-holding the 
patient was hyperventilated prior to the dynamic acquisi-
tion. The initial breath-hold in expiration was for the first 
30 s of the dynamic acquisition, and the second breath- 
hold, for the remainder of the dynamic acquisition. Be-
tween each breath-hold there was a short breathing in-
terval consisting of a single breath in and out. 
2.4.2. Tumour Acquisition 
The tumour acquisition was performed in a similar man- 
ner but centred on and encompassing the entire tumour. 
50 millilitres of iodinated contrast agent (ioversol 350 
mg/ml iodine; Optiray, Covidien, Mansfield, MA, USA) 
was administered intravenously at 5 ml/s using a dual 
headed pump (OptiVantage™ DH, Mallinckrodt, St 
Louis, Missouri, USA), followed by a 30 millilitres of 
saline flush at the same rate. After a delay of 4 - 10 s 
from the start of the injection, depending on the anatom-
ical position of the tumour, the post contrast dynamic 4D 
adaptive spiral acquisition encompassing the entire tu-
mour was obtained. The acquisition parameters are sum- 
marised in Table 1. 
2.5. Image Analysis 
The image analysis was carried out on a commercial 
workstation (MMWP, Siemens Healthcare, Forchheim, 
Germany) using validated commercial software (Decon-
volution algorithm, vPCT Body Software; Siemens 
Healthcare, Forchheim, Germany). The initial post-pro- 
cessing steps within the software platform included 1) 
motion correction and 2) application of the noise reduc-
tion filter. Motion correction was based on a non-rigid 
deformable registration technique [7], previously vali-
dated for lung and kidney data [8,9]. The arterial time- 
attenuation curve was defined by placing a region of in-
terest (ROI) within the artery in the field of view. Para-
metric maps of regional blood flow (BF; units: mL/min/ 
100mL), blood volume (BV; units: mL/100mL), and 
flow-extraction product (FE; units: mL/min/100mL), 
were then generated in axial, coronal and sagittal planes 
(Figure 1).  
A volume of interest was delineated around the entire 
renal cortex visible on the scan or for the entire tumour 
volume by a single radiologist with over 10 years’ expe-
rience of Perfusion CT techniques. The renal cortical 
margin on axial, sagittal and coronal planes were ma-
nually outlined simultaneously thus generating mean 
global parameter values for the entire volume of interest 
(Figure 1). 
 
 
(a)               (b)               (c) 
Figure 1. Parametric maps of (a) regional blood flow, (b) blood volume, (c) flow extraction product. 
Kidney
Tumour
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2.6. Statistical Analysis 
Statistical analysis was carried out using StatsDirect 
(Cheshire, UK), R version 2.15.2 (R Foundation for Sta-
tistical Computing, Vienna, Austria) & Microsoft Excel 
2000 (Microsoft, WA). For each patient, the difference 
between the measurements of a parameter at each repro-
ducibility scan and their mean value, d, was calculated. 
In order to establish whether the size of d was dependent 
on the parameter value, Kendall’s tau for correlation of 
the absolute value of d against the mean parameter value 
for the two scans was calculated. If this test demonstrated 
that the error was indeed proportional to the mean, at the 
95% confidence interval, then the data were transformed 
using natural logarithm, and Kendall’s tau test were then 
repeated.  
Reproducibility was assessed by Bland-Altman ap-
proach [10]—the mean within-patient difference and its 
95% confidence interval (mean difference ± 1.96 × stan-
dard deviations of the differences) were determined. We 
also calculated the 95% confidence interval for sponta-
neous changes which may occur in a group of patients as 
outlined by Galbraith [11].  
Within and between-patients co-efficients of variation 
(COV), together with intraclass correlation (ICC) were 
evaluated. 
3. Results 
3.1. Patients 
Patient characteristics are summarised in Table 2. All six 
patients underwent two baseline pre-treatment vPCT 
scans to assess reproducibility. Two patients were sub-
sequently withdrawn from the trial before L-NNA could 
be administered: one patient (Patient 1) developed a 
symptomatic pericardial effusion, precluding her contin-
uation in the trial, whilst the other patient (Patient 3) was 
found to have a persistently elevated blood pressure (an 
exclusion criterion) after trial registration and the initial 
baseline CTs, precluding trial drug administration. Of the  
four remaining patients, three received L-NNA at the 
Phase I study starting dose level of 0.7 mg/kg, and one 
received L-NNA at the next dose level, 0.9 mg/kg. 
3.2. Baseline Vascular Assessment and 
Reproducibility 
The reproducibility values for renal and tumour parame-
ters were assessed and the Bland Altman plots for all 
renal and tumor blood flow parameters are shown in 
Figure 2. Mean changes in each of the renal and tumour 
parameter for the whole cohort of patients were calcu-
lated and expressed as a percentage of the mean baseline 
values. The 95% confidence interval for spontaneous 
changes in the whole cohort of patients following L- 
NNA administration were determined on the basis of 
four renal and seven tumour measurements (seven sepa-
rate target lesions in four patients). For renal blood flow, 
blood volume & extraction fraction, these values were 
±10.79%, ±16.44% & ±11.07% respectively. For tumour 
blood flow, blood volume & extraction fraction, these 
values were ±9.99%, í6.52% to 6.98% & í8.29% to 
9.03% respectively. Changes beyond these ranges would 
be regarded as significant at the 5% level [11]. The in-
traclass correlation coefficients for renal blood flow, 
blood volume, extraction fraction & tumour blood flow, 
blood volume and extraction were 0.77, 0.28, 0.78, 0.94, 
0.99 & 0.94 respectively.  
3.3. Changes in Blood Pressure and Vascularity 
Post LNNA Administration 
L-NNA was well tolerated by all four patients.  A rise 
in the mean arterial blood pressure was observed in three 
out of the four patients between 1 and 2 hours after the 
administration of L-NNA (Figure 3). All three patients 
who experienced a transient rise in blood pressure were 
in the lower dose cohort (0.7 mg/kg). By 48 hours these 
had all returned back to baseline except for one patient. 
The maximal percentage changes in systolic & diastolic  
 
Table 2. Baseline characteristics of patients. 
 Patients 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Age 42 69 89 32 66 34 
Primary Breast Lung Prostate Lung Rectum Brain 
Histology Adenocarcinoma Glioblastoma Multiforme 
Size of lesions 
(largest dimension) 
Lesion 1 
10.7 cm 3.9 cm 8.4 cm 3.7 cm 5.6 cm 2.5 cm 
Lesion 2 
3.2 cm 2.8 cm  2.9 cm  3.3 cm 
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 tumour blood volume 
tumour extraction fraction renal extraction fraction  
renal blood volume  
 
Figure 2. Bland Altman plot of difference between the two studies against the mean for each parameter measured. Mean dif-
ference is indicated by the solid line. Two outer dotted lines represent 1.96× standard deviation of the differences on each side 
of the mean difference, which define the range within which 95% of differences between repeated measurements made on the 
same subject will lie. 
 
 
Figure 3. Change in blood pressure following L-NNA administration. 
 
blood pressure were 21% and 24% respectively. 
Statistically significant drop in the global renal blood 
flow (20%), blood volume (19.7%) & extraction fraction 
(21.6%) were seen one hour after L-NNA infusion but 
not at subsequent time points. Similarly, statistically sig-
nificant reduction in the tumour blood flow (16.9%) was 
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also seen one hour after L-NNA infusion but not subse-
quently. However, tumour blood volume & extraction 
fraction remained suppressed up to 72 hours after L- 
NNA infusion (Table 3). 
For patients 2, 4, and 6 who had two target lesions, 
changes in the vascular parameters following L-NNA for 
each lesion were calculated by taking the mean of the 
absolute changes at different time points and expressed 
as a percentage compared to the baseline pre-treatment 
values (Table 4). The magnitude of changes can differ 
significantly between the two target lesions in the same 
patient. It is uncertain whether these differences re- 
present genuine differential responses to L-NNA or vari-
ations associated with repeated measurements.  
The average values for the mean arterial blood pres-
sure taken between one and two hours after the adminis-
tration of L-NNA for each patient and their percentage 
change compared to baseline were calculated. Strong 
negative correlations were found between changes in the 
blood pressure and tumour blood flow and tumour blood 
volume evaluated one hour after L-NNA (Table 5). No 
such correlation was found between the change in blood 
pressure and renal blood supply. 
4. Discussion 
In normal vasculature, nitric oxide is released by endo-
thelial cells to promote smooth muscle relaxation in the 
blood vessels and vasodilatation. Despite the significant 
structural and physiological differences between normal 
and tumour vasculature [12], tumour blood flow is also 
maintained by nitric oxide in a similar manner.  
This is achieved directly by nitric oxide activating gu-
anylate cyclase to produce cyclic guanosine monophos-
phate (cGMP), which in turn triggers cGMP dependent 
protein kinases to promote myosin phosphorylation. In-
directly, NO also interacts with Vascular Endothelial 
Growth Factor (VEGF), another important vaso-active 
signalling agent, inhibition of which has shown activity 
against a range of tumours [13-17]. Expression of nitric 
oxide synthase (NOS), which catalyses the conversion of 
L-arginine into nitric oxide, is up-regulated by VEGF 
[18,19], whilst VEGF expression is down-regulated by 
nitric oxide [20]. Blockade of the NOS pathway has been 
shown to result in hypertension in humans [21] and im-
pact on renal blood flow and its autoregulation in animals 
[22-26]. Thus it has been suggested that the development 
of hypertension in patients on long term VEGF inhibitor 
treatment may in part be secondary to the suppression of 
nitric oxide production due to VEGF inhibition. 
Consistent with published results in animal and clini-
cal studies, we have demonstrated a reduction in renal 
blood flow, blood volume, and extraction fraction within 
one hour of L-NNA administration [22-26], and a tran-
sient increase in the systemic arterial blood pressure fol-
lowing the blockade of the nitric oxide synthase pathway 
[21]. Blood pressure began to normalise two hours after 
L-NNA administration, and renal perfusion returned to 
baseline by 24 hours post L-NNA. Findings from a pre-
vious study that tumour blood volume was reduced fol-
lowing L-NNA administration [27] has also been con- 
 
Table 3. % change in each parameter compared to their 
baseline value at different time points after the administra-
tion of L-NNA. 
 1 hour 24 hours 48 hours 72 hours 
Blood flow 
Renal í20.04% í7.11% í6.35% í4.42% 
Tumour í16.89% í9.74% í11.25% í9.28% 
Blood volume 
Renal í19.71% í10.16% 3.55% 8.32% 
Tumour í18.58% í7.84% í10.27% í10.45% 
Extraction fraction 
Renal í21.61% í5.84% í10.74% í9.39% 
Tumour í9.96% í8.94% í10.81% í7.19% 
 
Table 4. Variability in vascular parameters between different target lesions in the same patient pre and post LNNA treatment. 
Patient 
rBF (mL/min/100mL) rBV (mL/100mL) EF (mL/100mL/min) 
Lesion 1 Lesion 2 Lesion 1 Lesion 2 Lesion 1 Lesion 2 
2 
Pre 37.9 70.0 3.79 7.54 9.50 17.8 
Post í6.46% í18.2% í12.4% í22.1% 2.08% í23.3% 
4 
Pre 101 70.5 6.46 5.86 6.63 5.25 
Post í20.5% 5.15% í12.5% í12.9% í3.85% í26.7% 
6 
Pre 92.0 72.2 4.26 4.13 10.5 6.44 
Post í13.2% í20.3% í4.05% í17.7% í22.8% í9.22% 
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Table 5. Spearman rank correlation coefficient: íIRU%3
& tumour BF (p < 0.0001) & ííWRIRU%3
and tumour BV (p = 0.2). 
Patient ǻ%3EHWZHHQ h & 2 h post L-NNA) 
ǻWXPRXU%) h 
post L-NNA 
ǻWXPRXU%9K
post L-NNA 
2 5.7% í21% í29% 
4 2.7% í15% í18% 
5 14.7% í27% í28% 
6 í1.2% í9.8% í3.7% 
 
firmed. Improvements in CT technology which have 
translated into higher temporal resolution in our study 
have enabled us also to assess regional blood flow, and to 
demonstrate a corresponding decrease in blood flow in 
our study. Additionally, we have shown that this reduc-
tion can persist up to 72 hours after L-NNA. The pro-
longed effect of L-NNA on tumour vasculature, com-
pared to the renal vasculature, is consistent with observa-
tions in an animal study [3]. This differential effect of 
NOS blockade may be related to the increased expression 
of inducible NOS in tumours [28-30]. Variability in the 
expression by tumour perivascular cells of soluble gua-
nylate cyclase and phosphodiesterase, which produces 
and degrades cGMP respectively, has been proposed as 
another potential mechanism to account for this differen-
tial response [1]. The level of guanylate cyclase expres-
sion has recently been reported to be reduced in glioma 
tissues [31].  
The development of hypertension may be predictive of 
tumour response to anti-angiogenesis treatment [32-35]. 
The negative correlation observed in this small cohort of 
patients between the degree of vaso-constriction in the 
tumour blood supply, as reflected by a reduction in the 
tumour blood flow and volume, and the transient increase 
in blood pressure, warrants further investigations. Ap-
plying DCE-CT to evaluate changes in the tumour and 
systemic blood flow simultaneously and correlating them 
with the change in blood pressure may help to determine 
the utility of blood pressure change as a surrogate marker 
of the acute physiological effect of anti-angiogenic treat- 
ment on tumour vasculature. 
Our baseline vPCT reproducibility (within subject 
COV of 7.6% to 12.6% for the renal vasculature and 6.4 
to 10.3% for the tumour vasculature) and intraclass cor-
relation coefficient values of greater than 0.9 for tumour 
vascular parameters indicate that vPCT assessment of 
regional blood flow, blood volume and extraction factor 
can be used to monitor therapeutic changes. The repro-
ducibility for tumour is comparable to that obtained pre-
viously for patients with non small cell lung cancer [36] 
using a similar technique. Nevertheless, an important 
consideration in the Phase I setting is that baseline re-
producibility should be assessed for each individual pa-
tient, particularly where anticipated changes in vascular 
parameters caused by the vaso-active agent under inves-
tigation are small. Furthermore, consideration should 
also be given to the possibility of differential responses 
by different target lesions in the same patient, and the use 
of vPCT may be advantangeous in that vascular changes 
in multiple target lesions can be evaluated at the same 
time to provide a more global assessment of the efficacy 
of the agent than by evaluating changes in single index 
lesions. 
Whilst our findings suggest that the systemic effects of 
a single dose of a NOS inhibitor are transient, and that 
there is a differential effect on the systemic and tumour 
vasculature up to 72 hours post treatment, there are limi-
tations to this study. Our study population was highly 
selected and very small given the stringent exclusion 
criteria: 55 patients were excluded at screening but ne-
cessitated by the trial end point. Only 6 patients were 
recruited and 4 patients treated due to premature closure 
of the trial by the study sponsor for strategic reasons. 
They were also highly heterogeneous in terms of their 
primary cancer. 
5. Conclusion 
In summary, preliminary data in a small study population 
who received a one-off L-NNA treatment indicated that 
the blockade of the NOS pathway can lead to a transient 
increase in blood pressure and reduction in blood flow to 
the kidneys, and a more sustained decrease in tumour 
blood flow, volume & permeability. DCE-CT provides a 
robust imaging method to evaluate changes in renal and 
tumour blood flow following the administration of a va-
so-active drug. Change in blood pressure may be a useful 
surrogate marker for the acute response to anti-angio- 
genic treatment. 
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